SCHEMBL5833053

SCHEMBL5833053

N[C@@H](Cc1ccc(O)cc1S(=O)(=O)O)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.51
KDM4E B2RXH2 3/20 0.51
ALOX15 P16050 3/20 0.51
LMNA P02545 3/20 0.51
ALDH1A1 P00352 2/20 0.51
CYP3A4 P08684 2/20 0.51
MAPT P10636 2/20 0.51
NFKB1 P19838 2/20 0.51
BLM P54132 2/20 0.51
PMP22 Q01453 2/20 0.51
KMT2A Q03164 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
ADORA3 P0DMS8 2/20 0.51
HTR2A P28223 2/20 0.51
HTR1A P08908 1/20 0.51
TSHR P16473 1/20 0.51
HTR2C P28335 1/20 0.51
SLC6A4 P31645 1/20 0.51
HTR7 P34969 1/20 0.51
HTR2B P41595 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5833049 1.00 HSD17B10 (0.51) HSD17B10KDM4EALOX15LMNAALDH1A1
SCHEMBL2679928 0.82 KDM4E (0.66) HSD17B10KDM4EALOX15LMNAALDH1A1
SCHEMBL4140820 0.82 KDM4E (0.66) HSD17B10KDM4EALOX15LMNAALDH1A1
SCHEMBL1984486 0.80 SLC7A5 (0.53) HSD17B10KDM4EALOX15LMNAALDH1A1
SCHEMBL29475704 0.80 SLC7A5 (0.53) HSD17B10KDM4EALOX15LMNAALDH1A1
SCHEMBL1984487 0.80 SLC7A5 (0.53) HSD17B10KDM4EALOX15LMNAALDH1A1
SCHEMBL26664897 0.79 USP2 (0.50) HSD17B10KDM4EALOX15LMNAALDH1A1
SCHEMBL569807 0.79 SLC7A5 (0.58) HSD17B10KDM4EALOX15LMNAALDH1A1
SCHEMBL722789 0.78 KDM4E (0.56) HSD17B10KDM4EALOX15LMNAALDH1A1
SCHEMBL31189933 0.78 KDM4E (0.56) HSD17B10KDM4EALOX15LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050267035-A1 Peptide and polypeptide inhibitors of complement C1s ZYMOGENETICS, INC. 2005-12-01 US claimed
EP-1349874-A2 PEPTIDE AND POLYPEPTIDE INHIBITORS OF COMPLEMENT C1S ZymoGenetics, Inc. (US) 2003-10-08 EP claimed
US-20020102256-A1 Peptide and polypeptide inhibitors of complement C1s ZYMOGENETICS, INC. 2002-08-01 US claimed
WO-2001098365-A2 PEPTIDE AND POLYPEPTIDE INHIBITORS OF COMPLEMENT C1S ZYMOGENETICS, INC. (US) 2001-12-27 WO claimed
US-5858244-A COPOLYMER COMPRISING AT LEAST ONE OF N-OXYGENATEDHYDROCARBONAMIDE MONOMERS AND AT LEAST ONE OF AMINO ACID MONOMERS, POLYSUCCINIMIDES NALCO CHEMICAL COMPANY (US) 1999-01-12 US claimed
US-5776875-A Use of biodegradable polymers in preventing scale build-up NALCO CHEMICAL COMPANY (US) 1998-07-07 US claimed
EP-0819653-A2 Use of biodegradable polymers in preventing scale build-up NALCO CHEMICAL COMPANY (US) 1998-01-21 EP claimed
EP-2584037-B1 METHOD FOR CONSTRUCTING RECOMBINANT BACTERIUM FOR PRODUCING NON-NATIVE PROTEIN, AND UTILIZATION OF SAME RIKEN (JP) 2016-08-10 EP disclosed
US-9340790-B2 Method for constructing recombinant bacterium for producing non-native protein, and utilization of same RIKEN (JP) 2016-05-17 US disclosed
EP-2584037-A1 METHOD FOR CONSTRUCTING RECOMBINANT BACTERIUM FOR PRODUCING NON-NATIVE PROTEIN, AND UTILIZATION OF SAME Riken (JP) 2013-04-24 EP disclosed
US-20130095524-A1 METHOD FOR CONSTRUCTING RECOMBINANT BACTERIUM FOR PRODUCING NON-NATIVE PROTEIN, AND UTILIZATION OF SAME RIKEN (JP) 2013-04-18 US disclosed
US-7071299-B2 Peptide and polypeptide inhibitors of complement C1s ZYMOGENETICS, INC. (US) 2006-07-04 US disclosed
US-20050267035-A1 Peptide and polypeptide inhibitors of complement C1s ZYMOGENETICS, INC. 2005-12-01 US disclosed
EP-1349874-A2 PEPTIDE AND POLYPEPTIDE INHIBITORS OF COMPLEMENT C1S ZymoGenetics, Inc. (US) 2003-10-08 EP disclosed
US-20020102256-A1 Peptide and polypeptide inhibitors of complement C1s ZYMOGENETICS, INC. 2002-08-01 US disclosed
WO-2001098365-A2 PEPTIDE AND POLYPEPTIDE INHIBITORS OF COMPLEMENT C1S ZYMOGENETICS, INC. (US) 2001-12-27 WO disclosed
US-5858244-A COPOLYMER COMPRISING AT LEAST ONE OF N-OXYGENATEDHYDROCARBONAMIDE MONOMERS AND AT LEAST ONE OF AMINO ACID MONOMERS, POLYSUCCINIMIDES NALCO CHEMICAL COMPANY (US) 1999-01-12 US disclosed
US-5776875-A Use of biodegradable polymers in preventing scale build-up NALCO CHEMICAL COMPANY (US) 1998-07-07 US disclosed
EP-0819653-A2 Use of biodegradable polymers in preventing scale build-up NALCO CHEMICAL COMPANY (US) 1998-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267035-A1 Peptide and polypeptide inhibitors of complement C1s C1S, C1QBP, C1R HSD17B10 4791/4885KDM4E 4579/4885ALOX15 3472/4885
US-20020102256-A1 Peptide and polypeptide inhibitors of complement C1s C1S, C1QBP, C1R HSD17B10 4791/4885KDM4E 4579/4885ALOX15 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.